Effect of vitamin D supplementation in novel corona virus 2019
Phase 3
- Conditions
- Covid-19 disease.Use this code when COVID-19 has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms. Use additional code, if desired, to identify pneumonia or other manifestations.U07.1
- Registration Number
- IRCT20110726007117N11
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Age 30- 60 years old
Serum Vitamin D level lower than 30 nanograms per milliliter
Cases who diagnosed as novel coronavirus 2019 infection by clinical features (sore throat, dry cough, dyspnea), laboratory findings (positive C- Reactive protein, lymphocyte<1100 per mililiter), or radiological findings (lung patchy infiltrations in chest X-ray or CT scan)
Exclusion Criteria
Serum Vitamin D level upper than 30 nanograms per milliliter
Use of medications that interfere with vitamin D metabolism
History of hypercalcemia, kidney disorders, cirrhosis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method C-Reactive Protein level. Timepoint: Measurement of C-Reactive Protein level before starting intervention and 30 days after starting the intake of vitamin D supplementation. Method of measurement: enzyme-linked immunosorbent assay kit.
- Secondary Outcome Measures
Name Time Method